Clinical Trial Update: Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of PAC-1 in combination with entrectinib for metastatic uveal melanoma was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• Entrectinib (entrectinib)
• PAC-1 (PAC-1)

Snippet

Sponsor: Arkadiusz Z. Dudek, MD | Conditions: Uveal Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-11-22